PneumoNP Newsletter - March 2017

The latest trimetrial newsletter from PneumoNP is available.

Read here the latest progress of this project.


WHO's list of bacteria for which new antibiotics are urgently needed

WHO published on February 27th for the 1st time a list of antibiotic-resistant "priority pathogens", which includes 12 families of bacteria that pose the greatest threat to human health. The list is divided into three categories according to the urgency of need for new antibiotics: critical, high and medium priority.

The purpose of the list is to encourage governments to implement policies to incentivize basic science and advanced R&D by both publicly funded agencies and the private sector investing in new antibiotic discovery.

Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant is considered as a "High priority". Tuberculosis was not included in the list because it is targeted by other, dedicated programmes.

More information here.

News from ERINHA

The latest news from ERINHA are available here.

What is ERINHA?

The European Research Infrastructure on Highly Pathogenic Agents (ERINHA) is conceived to develop an adequate and coordinated effort of the European research capacities to address the challenges posed by these highly pathogenic micro-organisms infecting humans, with high risks for public health, society and the economy.

The ERINHA infrastructure will provide open access to state-of-the-art BSL4 facilities for the European scientific community to enhance basic and finalised research activities and diagnostic activities.

ERINHA's implementation is scheduled for 2017 so we are looking froward to this project progress.


More information on ERINHA on their website.

Publication: Strategic Research & Innovation Agenda

The European Technology Platform on Nanomedicine published this year together with Euromed2 the update of the Strategic Research & Innovation Agenda for Nanomedicine for 2016-2030.

This documents is intended to provide a framework for the deployment of innovative Nanomedicine solutions for healthcare and to provide public authorities, including the European Commission, with roadmap and priorities for research.

Infectious diseases and multidrug resistance resistance bacteria are still a priority.

To learn more, you can read the report here.


PneumoNP Newsletter - December 2016

The lateste trimetrial newsletter from PneumoNP is available.

Read here the latest progress of this project. 


The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.